A buyout is premature.
I'm more concerned about possible licensing deals being thrown in disarray. Not knowing the pricing and potential market size is going to throw a massive spanner. Any possible deals might be on the backburner for the next few months
2 of our big possible suitors are throwing big cash at US investment and now some companies are second guessing that investment. I would think all big pharma would be looking very closely at their financials.
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-invest-40-billion-us-over-5-years-ceo-says-2025-05-05/
https://www.fiercepharma.com/manufacturing/following-lilly-and-jj-novartis-unveils-23b-investment-beef-us-manufacturing-rd
https://firstwordpharma.com/story/5959828
Add to My Watchlist
What is My Watchlist?
